Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT02900651
- Locations
- 🇺🇸
Uni Of TX MD Anderson Cancer Cntr Dept of Onc, Houston, Texas, United States
🇺🇸UCSF ., San Francisco, California, United States
🇺🇸UCLA Santa Monica Hematology Oncology, Santa Monica, California, United States
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 458
- Registration Number
- NCT02896127
- Locations
- 🇬🇧
Novartis Investigative Site, Wigan, United Kingdom
Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma
Phase 3
Completed
- Conditions
- Mild Asthma
- Interventions
- Drug: QMF149 150/80 μgDrug: MF 200 μg
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 802
- Registration Number
- NCT02892344
- Locations
- 🇻🇳
Novartis Investigative Site, Hai Phong, Vietnam
Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT02892019
- Locations
- 🇹🇷
Novartis Investigative Site, Ankara, Turkey
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Phase 1
Completed
- Conditions
- Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 298
- Registration Number
- NCT02890069
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇬🇧Novartis Investigative Site, Oxford, United Kingdom
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02888080
- Locations
- 🇳🇱
Novartis Investigative Site, Rotterdam, Netherlands
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
Phase 4
Completed
- Conditions
- Heart Failure
- Interventions
- Drug: LCZ696 (sacubitril/valsartan)
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 794
- Registration Number
- NCT02887183
- Locations
- 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Phase 3
Completed
- Conditions
- Chronic Heart Failure (CHF)
- Interventions
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 592
- Registration Number
- NCT02884206
- Locations
- 🇬🇧
Novartis Investigative Site, Stevenage, United Kingdom
24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
Phase 4
Withdrawn
- Conditions
- Visual Impairment Due to Diabetic Macular Edema
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02878681
Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02878616
- Locations
- 🇺🇸
Novartis Investigative Site, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath